Victoria Johnson

Conaghan discussed findings from a phase 2 trial at the ACR 2024 Convergence.

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear.

Emapalumab may improve outcomes in patients with MAS whose disease didn’t respond to steroid therapy and mitigate the need for more toxic therapies.

Arnold discussed his research in analyzing and improving current classifications of ANA-RMDs and how it could help improve research in the field.

Tesser discussed the background of the phase 3 RESET-RA trial and efficacy findings.

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.

Noaiseh discussed data from the DAHLIAS study linking, for the first time, clinical responses, with autoantibody levels.

Over half of patients treated with LEVI-04 had at least a 50% reduction in pain and over 25% had at least a 75% reduction.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.

Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.

Just discussed data from 2 studies demonstrating efficacy of AI assessment compared to clinician assessment.

Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.

Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.

Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.

Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.

While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.

People that reported only some or none of their flares had almost twice the rate of gout flares in the last year than those reporting all of their flares.

Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.

Combining interventions yielded no significant differences in outcomes, pain, or quality-of-life.

Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.

The pain reduction effects did not last long beyond the scope of the trial, underscoring the importance of continuing such exercises.